China Net Finance, April 24th - Recently, China Net Finance learned from Zaiding Pharmaceutical that Zhu Tong, former Chief Operating Officer of Xiansheng Zaiding, will join the company as the Chief Business Officer of Greater China. And Liang Yi, former Chief Business Officer and President of Greater China, will resign at the end of April.
According to public information, before joining Zaiding Pharmaceutical, Zhu Tong had worked in well-known companies such as Xiansheng Pharmaceutical, AstraZeneca China, and Sanofi, and had extensive experience working in multinational pharmaceutical companies.
As an innovative pharmaceutical enterprise, Zaiding Pharmaceutical focuses its products on tumor, autoimmune disease, infectious diseases, central nervous system disease and other fields. At present, Zaiding Pharmaceuticals has 5 commercial products, including Zele, Aipu Dun, Qingle, Niu Zai Le, and Wei Weijia.
According to the performance announcement, in 2023, Zaiding Pharmaceutical achieved a revenue of 267 million US dollars, a year-on-year increase of 25%; The net loss narrowed to $335 million.
Since its listing in Hong Kong in September 2020, Zaiding Pharmaceutical has been continuously losing money. From 2020 to 2022, Zaiding Pharmaceutical achieved revenue of 48.958 million US dollars, 144 million US dollars, and 215 million US dollars, with year-on-year growth rates of 277.04%, 194.77%, and 49.01%, respectively; The net profits were -269 million US dollars, -704 million US dollars, and -443 million US dollars, respectively.
On the investor event day in June 2023, the management of Zaiding Pharmaceutical stated that the company will maintain a compound annual growth rate of over 50% in revenue for the next five years, from 2023 to 2028, achieving significant revenue growth and continuous improvement in operating profit margin, and achieving profitability by the end of 2025.